Formation of stacking complexes between caffeine (1,2,3-trimethylxanthine) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine may attenuate biological effects of this neurotoxin

Bioorganic Chemistry

Volumn 33, Issue 5, 2005, Pages 402-413

  Ulanowska, Katarzyna ^a   Piosik, Jacek ^a   Gwizdek Wiśniewska, Anna ^b   Weģrzyn, Grzegorz ^a,c  

^a UNIVERSITY OF GDA SK   (Poland)

^b GDANSK UNIVERSITY OF TECHNOLOGY   (Poland)

^c INSTITUTE OF OCEANOLOGY   (Poland)

Author keywords

1,2,3 trimethylxanthine; 1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Mutagenicity; Parkinson's disease; Stacking complexes

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADENOSINE A2 RECEPTOR; CAFFEINE DERIVATIVE; CAFFEINE(1,2,3 TRIMETHYLXANTHINE); NEUROTOXIN; UNCLASSIFIED DRUG;

ARTICLE; COMPLEX FORMATION; MOLECULAR MODEL; MUTAGENICITY; NEUROTOXICITY; PRIORITY JOURNAL; RECEPTOR BLOCKING; VIBRIO HARVEYI;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; CAFFEINE; CALORIMETRY; HUMANS; MODELS, MOLECULAR; MUTAGENICITY TESTS; NEUROTOXINS; PARKINSONIAN DISORDERS; VIBRIO;

ANIMALIA;

EID: 26044478153     PISSN: 00452068     EISSN: 10902120     Source Type: Journal    
DOI: 10.1016/j.bioorg.2005.07.004     Document Type: Article

References (46)

1. T. Fukuda Neuropathology 21 2001 323 332
2. N. Schmidt, and B. Ferger J. Neural. Transm. 108 2001 1263 1282
3. S.G. Speciale Neurotoxicol. Teratol. 24 2002 607 620
4. W. Dauer, and S. Przedborski Neuron 39 2003 889 909
5. O. Eberhardt, and J.B. Schulz Toxicol. Lett. 139 2003 135 151
6. P. Jenner Parkinsonism Relat. Disord. 9 2003 131 137
7. S. Przedborski, and M. Vila Ann. N.Y. Acad. Sci. 991 2003 189 198
8. P.J. Blanchet, F. Calon, M. Morissette, A.H. Tahar, N. Belanger, P. Samadi, R. Grondin, L. Gregoire, L. Meltzer, T. Di Paolo, and P.J. Bedard Parkinsonism Relat. Disord. 10 2004 297 304
9. S. Przedborski, K. Tieu, C. Perier, and M. Vila J. Bioenerg. Biomembr. 36 2004 375 379
10. A. Schober Cell Tissue Res. 318 2004 215 224
11. G.W. Ross, R.D. Abbott, H. Petrovitch, D.M. Morens, A. Grandinetti, K.H. Tung, C.M. Tanner, K.H. Masaki, P.L. Blanchette, J.D. Curb, J.S. Popper, and L.R. White JAMA 283 2000 2674 2679
12. A. Ascherio, S.M. Zhang, M.A. Hernan, I. Kawachi, G.A. Colditz, F.E. Speizer, and W.C. Willett Ann. Neurol. 50 2001 56 63
13. E.K. Tan, C. Tan, S.M. Fook-Chong, S.Y. Lum, A. Chai, H. Chung, H. Shen, Y. Zhao, M.L. Teoh, Y. Yih, R. Pavanni, V.R. Chandran, and M.C. Wong J. Neurol. Sci. 216 2003 163 167
14. J.F. Chen, K. Xu, J.P. Petzer, R. Staal, Y.H. Xu, M. Beilstein, P.K. Sonsalla, K. Castagnoli, N. Castagnoli Jr., and M.A. Schwarzschild J. Neurosci. 21 2001 RC143
15. K. Xu, Y.H. Xu, J.F. Chen, and M.A. Schwarzschild Neurosci. Lett. 322 2002 13 16
16. M.S. Gevaerd, R.N. Takahashi, R. Silveira, and C. Da Cunha Brain Res. Bull. 55 2001 101 106
17. G.W. Ross, and H. Petrovitch Drugs Aging 18 2001 797 806
18. S. Shiozaki, S. Ichikawa, J. Nakamura, S. Kitamura, K. Yamada, and Y. Kuwana Psychopharmacology 147 1999 90 95
19. J.F. Chen, S. Steyn, R. Staal, J.P. Petzer, K. Xu, C.J. Van Der Schyf, K. Castagnoli, P.K. Sonsalla, N. Castagnoli Jr., and M.A. Schwarzschild J. Biol. Chem. 277 2002 36040 36044
20. M.A. Schwarzschild, K. Xu, E. Oztas, J.P. Petzer, K. Castagnoli, N. Castagnoli Jr., and J.F. Chen Neurology 61 2003 S55 S61
21. M. Zdunek, J. Piosik, and J. Kapuscinski Biophys. Chem. 84 2000 77 85
22. J. Kapuscinski, B. Ardelt, J. Piosik, M. Zdunek, and Z. Darzynkiewicz Biochem. Pharmacol. 63 2002 625 634
23. J. Piosik, M. Zdunek, and J. Kapuscinski Biochem. Pharmacol. 63 2002 635 646
24. J. Piosik, K. Ulanowska, A. Gwizdek-Wisniewska, A. Czyz, J. Kapuscinski, and G. Wegrzyn Mutat. Res. 530 2003 47 57
25. A. Czyz, J. Jasiecki, A. Bogdan, H. Szpilewska, and G. Wegrzyn Appl. Environ. Microbiol. 66 2000 599 605
26. A. Czyz, H. Szpilewska, R. Dutkiewicz, W. Kowalska, A. Biniewska-Godlewska, and G. Wegrzyn Mutat. Res. 519 2002 67 74
27. G. Wegrzyn, and A. Czyz J. Appl. Microbiol. 95 2003 1175 1181
28. R. Belas, A. Mileham, D. Cohn, M. Hilman, M. Simon, and M. Silverman Science 218 1982 791 793
29. G. Klein, R. Walczak, E. Krasnowska, A. Blaszczak, and B. Lipinska Mol. Microbiol. 16 1995 801 811
30. A.S. Kalgutkar, S. Zhou, O.A. Fahmi, and T.J. Taylor Drug Metab. Dispos. 31 2003 596 605
31. J.R. Cashman Toxicology 43 1987 173 182
32. A. Czyz, W. Kowalska, and G. Wegrzyn Bull. Environ. Contam. Toxicol. 70 2003 1065 1070
33. J. Kapuscinski, and M. Kimmel Biophys. Chem. 35 1993 46 53
34. R.W. Larsen, R. Jasuja, R.K. Hetzler, P.T. Muraoka, V.G. Andrada, and D.M. Jameson Biophys. J. 70 1996 443 452
35. D.B. Davies, D.A. Veselkov, L.N. Djimant, and A.N. Veselkov Eur. Biophys. J. 30 2001 354 366
36. A.N. Veselkov, M.P. Evstigneev, D.A. Veselkov, and D.B. Davies J. Chem. Phys. 115 2001 2252 2266
37. D.B. Davies, D.A. Veselkov, M.P. Evstigneev, and A.N. Veselkov J. Chem. Soc. Perkin Trans. 2 2001 61 67
38. S.C. Yang, S.P. Markey, K.S. Bankiewicz, W.T. London, and G. Lunn Lab. Anim. Sci. 38 1988 563 567
39. R.R. McCusker, B.A. Goldberger, and E.J. Cone J. Anal. Toxicol. 27 2003 520 522
40. M. Thiruchelvam, E.K. Richfield, B.M. Goodman, R.B. Baggs, and D.A. Cory-Slechta Neurotoxicology 23 2002 621 633
41. J.K. Andersen Neurotoxicol. Res. 5 2003 307 313
42. B.K. Barlow, E.K. Richfield, D.A. Cory-Slechta, and M. Thiruchelvam Dev. Neurosci. 26 2004 11 23
43. J.A. Firestone, T. Smith-Weller, G. Franklin, P. Swanson, W.T. Longstreth Jr., and H. Checkoway Arch. Neurol. 62 2005 91 95
44. A. Storch, S. Ott, Y.I. Hwang, R. Ortmann, A. Hein, S. Frenzel, K. Matsubara, S. Ohta, H.U. Wolf, and J. Schwarz Biochem. Pharmacol. 63 2002 909 920
45. H. Elkon, E. Melamed, and D. Offen Mol. Neurosci. 24 2004 387 400
46. T.R. Guilarte Is methamphetamine abuse a risk factor in parkinsonism? Neurotoxicology 22 2001 725 731